FD 104 - Falha de tramento com análogos do GLP-1: como definir e o que fazer?

Neste FD vamos discutir sobre a falha de resposta ao tratamento da obesidade e diabetes com uso dos análogos do GLP-1: como definir, o que avaliar e o que fazer.

Acesse endodirect.com.br e siga @endodirect

Principais referencias:

American Diabetes Association Professional Practice Committee for Obesity. Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity. BMJ Open Diabetes Res Care. 2026

Kokkinos A, Thethi T, Lee CJ, Neff LM, Stefanski A, Cao D, et al. Tirzepatide efficacy and tolerability according to early weight response: a post hoc analysis of the SURMOUNT-1 and SURMOUNT-2 trials. Diabetes Obes Metab. 2026

Kuryłowicz A, Czupryniak L. Responders vs. non-responders or how to predict the response to GLP-1 or GLP-1/GIP receptor agonist therapy. Diabetes Obes Metab. 2026

Ko D, Kim DH, Tan FXN, Ho GJK, Chandra R, Xuan ZZ, et al. Suboptimal therapeutic responses associated with semaglutide in type 2 diabetes and obesity: a meta-analysis of randomized controlled trials. Cell Rep Med. 2026

Lu D, Li N, Yuan Z, Gao Y. Weight reduction heterogenicity and mediators of GLP-1RAs and dual agonists for individuals with obesity: a meta-analysis. Clin Obes. 2026

Billings LK, Winne L, Sharma P, Gomez-Valderas E, Chivukula KK, Kwan AYM. Comparison of dose escalation versus switching to tirzepatide among people with type 2 diabetes inadequately controlled on lower doses of dulaglutide: a randomized clinical trial. Ann Intern Med. 2025